Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corticosteroids after anaphylaxis discharge
ACTRN12624001339549Phase 3Not yet recruiting
- Sponsor
- Te Whatu Ora
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of prednisone and prednisolone in anaphylaxis (2 arms), sponsored by Te Whatu Ora. Primary endpoint: Incidence of biphasic reaction within 72 hours of initial anaphylactic episode. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
prednisoneprednisolone
03
Conditions
anaphylaxis
Beyond the preview
Go deeper on ACTRN12624001339549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001339549.